Dr. Reddy's Laboratories
243 hedge funds and large institutions have $1.46B invested in Dr. Reddy's Laboratories in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 115 reducing their positions, and 33 closing their positions.
1,777% more call options, than puts
Call options by funds: $244K | Put options by funds: $13K
6% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 33
1.05% less ownership
Funds ownership: 14.21% → 13.16% (-1.1%)
1% less funds holding
Funds holding: 246 → 243 (-3)
22% less capital invested
Capital invested by funds: $1.87B → $1.46B (-$413M)
50% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 115
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$23.2M |
| 2 |
Millennium Management
New York
|
+$20.8M |
| 3 |
CLGM
Capitolis Liquid Global Markets
New York
|
+$10.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$8.28M |
| 5 |
AIM
Aikya Investment Management
London,
United Kingdom
|
+$8.14M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$34.8M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$31.7M |
| 3 |
BlackRock
New York
|
-$21.4M |
| 4 |
Goldman Sachs
New York
|
-$13.8M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$13.6M |
RDY Hedge Fund Activity: Q1 2025 in Review
243 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q1 2025, worth a combined $1.46B — down 22% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new RDY positions and 33 closed out — a net gain of 2 holders — while 58 added to existing stakes and 115 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $23.2M. The largest seller was Morgan Stanley, cutting an estimated $34.8M.
- 243 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q1 2025, down from 246 in Q4 2024.
- Funds reported $1.46B of Dr. Reddy's Laboratories stock for Q1 2025, down 22% quarter-over-quarter.
- 35 funds opened new Dr. Reddy's Laboratories positions in Q1 2025 and 33 closed out, a net change of +2 holders.
- The largest Dr. Reddy's Laboratories buyer in Q1 2025 was BNP Paribas Financial Markets, an estimated $23.2M added.
- The largest Dr. Reddy's Laboratories seller in Q1 2025 was Morgan Stanley, an estimated $34.8M sold.
Based on aggregated 13F filings for Q1 2025.